Loading page…

Mankind Pharma Limited (MANKIND) · mywealthgrid

About

Mankind Pharma Limited operates in pharmaceuticals within the Healthcare sector, with consolidated revenues around ₹4,000 Cr and standalone quarterly revenue of ₹2,600–₹3,600 Cr. The company is profitable with EPS ranging ₹9.90–₹17.29 and operating margins typically 25–35% on a standalone basis, but trades at elevated valuation (PE 48.44) relative to its ROE of 12.49%.

Founded: 1995
Face value: ₹1

Market cap

₹1,04,696 Cr

P/E

50.6×

P/B

6.4×

Dividend yield

ROE

12.5%

ROCE

14.2%

Debt / equity

0.39

OPM

25.3%

EPS (TTM)

₹50.1

Book value

₹394.9

52-week high

₹2,617.9

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE of 48.44 versus ROE of 12.49% reflects high growth expectations—limited buffer if earnings growth disappoints.
Net profit (₹413.88–₹713.61 Cr) and OPM (24.92%–35.59%) volatility across quarters—verify if driven by seasonality, mix, or operational inconsistency.
1-year negative return (-4.44%) suggests market concerns—verify if rooted in valuation, competitive pressure, or operational issues.
Minimal public float (2.53%) with heavy promoter concentration (72.63%)—verify liquidity constraints and equity market accessibility.

Generated analysis · source review pending

Growth drivers

Consolidated revenue (₹4,030 Cr Jun 2026) significantly exceeds standalone (₹2,964 Cr)—verify if subsidiary contribution from recent M&A or organic growth will continue.
Standalone OPM at 31.33% (Jun 2026) above company average 25.34%—verify if recent margin expansion reflects operational improvements or one-time items.
Quarterly EPS ranges ₹9.90–₹17.29 with recent strength—verify drivers of volatility and sustainability of recent profitability levels.

Generated analysis · source review pending

₹2,535.0+2.1%1Y

Beta

0.47

Damps index moves

Volatility (1y)

26.2%

Annualised, daily returns

RSI (14)

74.4

Overbought territory

Rel. strength (1y)

-8.4%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Healthy operating margin of 25.3%
+Revenue CAGR of 17.7% over the last 3 years
+High promoter holding of 72.6% with no pledge

Cons

−Low dividend payout of 2% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 47
Growth: 69
Valuation: 25
Momentum

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 50 NIFTY MIDCAP 150 NIFTY 200 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	7,782	8,749	10,335	12,207	14,278
COGS	2,422	2,914	3,210	3,489	4,052
Gross profit	5,360	5,836	7,125	8,718	10,226
	3,370	3,923	4,575	5,688	6,596
	1,989	1,913	2,550	3,030	3,629
OPM %	25.6%	21.9%	24.7%	24.8%	25.4%
Depreciation	167	326	398	621	886
Interest	59	44	34	429	639
	196	129	281	541	229
Profit before tax	1,975	1,671	2,399	2,521	2,333
Tax	522	362	458	510	395
Tax %	26.4%	21.6%	19.1%	20.2%	16.9%
	1,453	1,310	1,942	2,011	1,938
PAT margin %	18.7%	15%	18.8%	16.5%	13.6%
EPS (₹)	35.8	32	47.8	49.3	46.4
EPS adjusted (₹)	36.3	32	47.8	48.1	46.3
Annual report	—	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	40	40	40	40	41	41
Reserves	—	6,115	7,395	9,323	14,291	16,259
Minority interest	—	161	188	213	236	261
	—	873	170	207	8,511	6,312
	—	1,958	1,922	2,180	4,680	5,207
Total equity & liabilities	—	9,148	9,715	11,963	27,760	28,080
	1,659	3,583	4,245	4,540	19,004	18,620
CWIP	—	670	493	207	306	655
Investments	—	1,115	1,352	2,573	2,042	1,985
	—	3,780	3,625	4,643	6,407	6,819
Total assets	—	9,148	9,715	11,963	27,760	28,080

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	920	1,813	2,152	2,413	3,121
	-1,369	-1,054	-2,082	-12,683	-196
	605	-740	5	10,290	-2,953
Net cash flow	155	19	76	21	-28
Free cash flow	455	1,024	1,837	1,953	2,495
CFO / Operating profit %	46.2%	95.4%	84.9%	80%	86.3%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	68.9%	66.7%	68.9%	71.4%	71.6%
EBITDA margin %	25.6%	21.7%	24.5%	24.7%	25.3%
EBIT margin %	23.4%	18%	20.7%	19.6%	19.1%
PAT margin %	18.7%	15%	18.8%	16.5%	13.6%
Working capital
Receivable days	18	24	30	46	44
Inventory days	265	188	177	219	193
Payable days	162	126	125	119	121
NWC days	121	85	81	146	117
Leverage
Current ratio	1.68	2.38	3.14	1.27	1.1
Debt to EBITDA	0.44	0.09	0.08	2.82	1.74
Debt to equity	0.14	0.02	0.02	0.59	0.39
Interest coverage	34.4	38.3	72.1	6.8	4.8
Asset turnover	0.85	0.9	0.86	0.44	0.51
Return ratios
Return on assets %	15.9%	13.5%	16.2%	7.2%	6.9%
Return on capital employed %	30.9%	23.7%	27.3%	18.4%	14.2%
Return on equity %	23.6%	17.6%	20.7%	14%	11.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	76.5%	76.5%	74.88%	74.87%	74.87%	72.71%	72.7%	72.68%	72.67%	72.66%	72.66%	72.63%
	4.18%	6.74%	9.87%	11.58%	12.37%	13.34%	12.92%	13.07%	12.84%	11.34%	10.24%	9.45%
	4.56%	9.79%	11.14%	9.95%	9.9%	11.06%	11.48%	11.5%	11.92%	13.25%	14.46%	15.39%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	14.76%	6.97%	4.11%	3.6%	2.86%	2.89%	2.9%	2.75%	2.57%	2.75%	2.64%	2.53%
No. of shareholders	—	—	—	—	—	—	—	—	1,70,347	1,77,539	1,77,606	1,66,715

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹2,503.8 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹2,502.3	-44.7	-1.8%	₹2,502.3	11,387	+650	3,831	250
23 Nov 2026	₹2,500.2	-54.8	-2.1%	₹2,500.2	121	+55	136	250
29 Dec 2026	₹2,504.0	-78.8	-3.1%	₹2,543.3	8	+8	9	250

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

50

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
0	0	0	₹0.0	1,880

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

101

across 15 fund houses

Held by these funds

6.18%

of the company's equity

All mutual funds

10.87%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

101 schemes · 15 fund houses

		Shares
Large Cap Fund	SBI Mutual Fund	40.73 L	985.32	1.79%	0.986%	-0
Growth Mid Cap FundNEW	Nippon India Mutual Fund	39 L	943.49	1.81%	0.944%	—
LARGE CAP FUND	Nippon India Mutual Fund	19.35 L	468.02	0.86%	0.468%	+1.91 L
PHARMA FUND	Nippon India Mutual Fund	16.04 L	387.93	4.09%	0.388%	+1.99 L
Healthcare FundNEW	ICICI Prudential Mutual Fund	15.07 L	364.6	5.21%	0.365%	—
ELSS- Tax Saver Fund	Axis Mutual Fund	13.93 L	337.01	1.03%	0.337%	-0
Contra Fund	SBI Mutual Fund	13.28 L	321.28	0.68%	0.322%	-0
Franklin India Mid Cap Fund (Formerly known as Franklin India Prima Fund) ^	Franklin Templeton Mutual Fund	10.29 L	248.96	1.91%	0.249%	-0

1–8 of 101

1 / 13

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Interim dividend8 Aug 2025 · ex-date₹1

1

Board meeting to consider results30 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

154 announcementsExport CSV

11 Jul 2026, 1:31 pmCompany Update

Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

Diversification / Disinvestment PDF

11 Jul 2026, 1:27 pmCompany Update

Announcement under Regulation 30 (LODR)-Acquisition

Acquisition PDF

11 Jul 2026, 1:23 pmOthers

Board Meeting Outcome for Outcome Of Board Meeting

Outcome without intimation PDF

10 Jul 2026, 11:12 amCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

10 Jul 2026, 9:47 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

9 Jul 2026, 5:03 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

9 Jul 2026, 4:55 pmOthers

Regulation 53 (1) Annual Report.

Exchange filing PDF

9 Jul 2026, 4:46 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

Date	Category	Subject	Filing
11 Jul 2026, 1:31 pm	Company Update Diversification / Disinvestment	Announcement under Regulation 30 (LODR)-Diversification / Disinvestment	PDF
11 Jul 2026, 1:27 pm	Company Update Acquisition	Announcement under Regulation 30 (LODR)-Acquisition

Loading announcements…

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

103 deals · 20 Oct 2023 – 14 Oct 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
14 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	55,000	₹2,430.00	₹13.37 Cr
14 Oct 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	55,000	₹2,430.00	₹13.37 Cr
13 Oct 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	42,245	₹2,440.00	₹10.31 Cr
13 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	42,245	₹2,440.00	₹10.31 Cr
9 May 2025	COPTHALL MAURITIUS INVESTMENT LIMITED	Block	BSE	Sell	55,000	₹2,434.10	₹13.39 Cr
9 May 2025	GOLDMAN SACHS (SINGAPORE) PTE.- ODI	Block	BSE	Buy	55,000	₹2,434.10	₹13.39 Cr
5 Feb 2025	COPTHALL MAURITIUS INVESTMENT LIMITED	Block	NSE	Sell	45,000	₹2,555.10	₹11.50 Cr
5 Feb 2025	ORBIMED GENESIS MASTER FUND L.P.	Block	NSE	Buy	45,000	₹2,555.10	₹11.50 Cr
10 Jul 2024	HEMA CIPEF (I) LIMITED	Block	NSE	Sell	18,50,850	₹2,082.00	₹385.35 Cr
10 Jul 2024	ICICI PRUDENTIAL MUTUAL FUND A/C ICICI PRUDENTIAL INDIA OPPORTUNITIES FUND	Block	NSE	Buy	4,37,238	₹2,082.00	₹91.03 Cr

1–10 of 103

1 / 11

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mankind Pharma Limited

Mankind Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

3

50

Fund holders

Documents

Announcements

Events

1

1

Announcements

1

1

3

50

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Mankind Pharma Limited

Mankind Pharma Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Futures3

Option chain50

Fund holders

Documents

Announcements

Events

Dividends1

Board meetings1

Announcements

Dividends1

Board meetings1

Ratio timeline

Futures3

Option chain50

Announcements

Quarterly record

Annual reports

Credit ratings

Investor Presentation and earnings call

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

3

50

1

1

1

1

3

50